{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-019161","form_type":"8-K","ticker":"RLYB","cik":"0001739410","company_name":"Rallybio Corp","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.328507+00:00","generated_at":"2026-06-15T09:35:38.621919+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Rallybio Q1 net loss $17.3M; cash $150.4M; RLYB212 data expected Q4 2023","bullets":["Net loss $17.3M ($0.43 per share) vs $14.5M ($0.48) in Q1 2022.","Cash, cash equivalents and marketable securities $150.4M as of March 31, 2023; runway into Q1 2025.","RLYB212 multiple dose cohort initiated; Phase 1b data to be presented at ISTH June 2023; cohort data expected Q4 2023.","RLYB116 multiple ascending dose study ongoing; initial safety, PK and PD data expected Q4 2023.","Research collaboration with EyePoint announced for sustained intraocular delivery of C5 inhibitor targeting geographic atrophy."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-019161","json":"https://secwatch.observer/filing/0000950170-23-019161.json","markdown":"https://secwatch.observer/filing/0000950170-23-019161.md","text":"https://secwatch.observer/filing/0000950170-23-019161.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1739410/000095017023019161/0000950170-23-019161-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1739410/000095017023019161/rlyb-20230509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T09:35:38.621919+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bdc1e97116d644b99d6f82d0a27f362a0815c192","claim":"Rallybio Corp reported first quarter ended March 31, 2023 results: net income $17.3 million, EPS $0.43.","evidence_excerpt":"Net loss was $17.3 million for the first quarter of 2023, or net loss per common share of $0.43 compared to a net loss of $14.5 million, or net loss per common share of $0.48 for the first quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1739410/000095017023019161/0000950170-23-019161-index.htm","confidence":0.99,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Net income","value":"$17.3 million"},{"label":"EPS","value":"$0.43"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}